Cyrus Therapeutics Inc.
- Biotech or pharma, therapeutic R&D
Cyrus Therapeutics Inc. is a clinical trial-ready stage biotechnology company (CYRS1542, GSPT1 Molecular Glue Degrader, US IND No.: 174397) focused on discovering and developing innovative medicines to address chronic or life-threatening diseases with significant unmet medical needs.
Our lead program, CYRS1542 (GSPT1 Molecular Glue Degrader), is being developed for indications including neuroendocrine cancers such as small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC), and neuroendocrine prostate cancer (NEPC), as well as metastatic castration-resistant prostate cancer (mCRPC).
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}